Therefore, we assessed CD47 expression not only tumor cells (TPS) but also combined with immune cells (CPS) in current study (TPS and CPS commonly utilized in the evaluation of immunotherapy biomarkers, including in PD-1/PD-L1 inhibitor studies approved in Japan [22–24]). This evidence concerns the gene CD47 and neoplasm.